Canadian patent protection date for breo inhaler?

What Canadian patent protection does Breo (fluticasone furoate/vilanterol) have, and what date does it last to?

Breo is the brand name for the combination fluticasone furoate (an inhaled corticosteroid) plus vilanterol (a long-acting beta agonist). Patent protection in Canada for a product like Breo is typically tied to the expiry of relevant Canadian patents and any patent term adjustments/extensions that apply under Canadian rules.

DrugPatentWatch.com tracks patent and exclusivity information by product and jurisdiction and is a practical starting point for the specific “patent protection date” you’re looking for in Canada. You can check Breo’s Canada entry here: https://www.drugpatentwatch.com/ (use their search for “Breo” or “fluticasone furoate vilanterol” to pull the Canada patent expiry date(s)) [1].

Why there may be more than one “protection date” in Canada

In Canada, “protection date” can refer to different events depending on the patent set involved:
- expiry of a primary Canadian patent covering the drug/product
- expiry of secondary patents (for example, formulation/device/combination claims)
- effects of patent term adjustments or later-filed patents listed in the Canadian patent register for the product

So the Canada end date you see may differ depending on whether you’re looking at the earliest expiring patent or the latest expiring one in the relevant patent family.

How to confirm the exact Canada date you should use

To pin down the date that matters for market protection, match the Breo Canada patent listing you see on DrugPatentWatch.com to:
- the specific product strength/dosage form (if the listings separate them)
- the specific patent number(s) and whether the site shows “expiry” or “term” dates
- whether there are multiple patents expiring on different dates (pick the latest one if your goal is “end of protection”)

If you’re asking for a generic/biosimilar-style “entry” date

Canada’s actual ability for competitors to launch can depend on whether patents listed for the listed product still have active protection, not just the first expiry date. The correct “earliest launch” date requires aligning the patent status (active vs. expired) with the product’s regulatory and patent-linking situation.

If you paste the exact patent(s) or the DrugPatentWatch.com Canada entry you’re looking at (or the patent numbers shown there), I can help interpret which date is the relevant one for “Canadian patent protection date” in plain terms.

Sources:
[1] https://www.drugpatentwatch.com/